SEC Form 424B4 filed by Sonnet BioTherapeutics Holdings Inc.
$SONN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/9/2022 | $5.00 → $2.00 | Buy | BTIG |
| 12/20/2021 | $8.00 → $2.50 | Buy | Chardan Capital |
| 12/16/2021 | $2.00 | Buy | HC Wainwright & Co. |
| 9/15/2021 | $5.00 | Buy | BTIG |
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. Dr. McAndrew brings more than 30 years of experience with various business models and types of transactional agreements involving biologics at different stages of development. During the course of his tenure at Sonnet, Dr. McAndrew has served as Vice President and then Senior Vice President, Business Development, and has been responsible for developing and leading the Compa
Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting in a partial response (PR) Continued progress with clinical trials evaluating SON-1010 in combination with Atezolizumab, for Platinum-Resistant Ovarian Cancer (PROC) and in combination with trabectedin in certain advanced soft-tissue sarcomas (STS) SON-1210 bifunctional Interleukins 12 and 15, on FHAB platform, in combination with chemotherapy for the treatment of advanced solid tumors and metastatic pancreatic cancer expected to initiate cli
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins In addition to the U.S. and EU, Sonnet's global IP coveragenow extends to China, Japan, Russia and New Zealand Management releases "What This Means" segment discussing the newly granted EU patent; Access here PRINCETON, NJ, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that the European Patent Office (EPO) has granted Patent No. EP3583125 B1, entitled "Albumin Binding Domain Fusion Proteins,"
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. Dr. McAndrew brings more than 30 years of experience with various business models and types of transactional agreements involving biologics at different stages of development. During the course of his tenure at Sonnet, Dr. McAndrew has served as Vice President and then Senior Vice President, Business Development, and has been responsible for developing and leading the Compa
Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC)The BAC will advise the company on business collaborations, communications and interactions with the Federal GovernmentPRINCETON, NJ / ACCESSWIRE / September 26, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that Lori McNeill has been appointed to the Company's Board of Directors. Ms. McNeill's Board position will also round out the composition of the compan
PRINCETON, NJ / ACCESSWIRE / March 22, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca, as Head of Clinical Operations, effective March 22, 2021. "I am pleased to welcome Richard and Manuel to Sonnet at such an exciting time as we prepare to enter SON-1010, our proprietary fully human Interleukin 12 (IL-12) therapeutic candidate configured with our Fully Human Albumin Binding (FHAB) technology, into the clinic," said Pankaj Mohan, Ph.D., Founder and CEO. "Richard is a seasoned
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)
10-Q - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
8-K - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
EFFECT - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
BTIG reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00 from $5.00 previously
Chardan Capital reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.50 from $8.00 previously
HC Wainwright & Co. initiated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)